Literature DB >> 33530892

Prevalence of bacterial sexually transmitted infections and coinfection with HIV among men who have sex with men and transgender women in Tijuana, Mexico.

Claire C Bristow1, Cristina Espinosa da Silva1, Alicia H Vera2, Jesus E Gonzalez-Fagoaga2,3, Gudelia Rangel3,4, Heather A Pines1.   

Abstract

We estimated the prevalence of syphilis and Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections, as well as human immunodeficiency virus (HIV) coinfection among cisgender men who have sex with cisgender men (MSM) and transgender women (TW) in Tijuana, Mexico. MSM and TW (N = 212) recruited via respondent-driven and venue-based sampling for HIV testing underwent sexually transmitted infection (STI) testing and completed interviewer-administered surveys in this study (2017-2018). Treponemal rapid tests were used at the point-of-care with positives undergoing confirmatory testing following the reverse syphilis-testing algorithm. Nucleic acid amplification testing of urine and swabs (rectal and pharyngeal) was used to detect CT/NG at three anatomic sites. Chi-squared tests were used to compare STI prevalence by HIV status. Sexually transmitted infection prevalence was 39.6% overall but higher for newly diagnosed HIV-positive (55.7%; N = 88) than HIV-negative (28.2%; N = 124) participants (p-value < 0.0001). Among newly diagnosed HIV-positive participants, the prevalence of syphilis was 35.2% (31/88), CT infection was 27.3% (24/88; nine urethral; 16 rectal; four pharyngeal), and NG infection was 26.1% (23/88; six urethral; 19 rectal; nine pharyngeal). Among HIV-negative participants, the prevalence of syphilis was 12.1% (15/124), CT infection was 13.7% (17/124; seven urethral; nine rectal; two pharyngeal), and NG infection was 9.7% (12/124; three urethral; seven rectal; seven pharyngeal). Over 60% of all CT (25/41) and NG (26/35) infections in the full sample occurred extragenitally in the absence of urethral infections, and over 80% of rectal (30/37) and pharyngeal (16/18) infections were asymptomatic. The high prevalence of syphilis, CT, and NG infections among MSM and TW in Tijuana suggests STI screening that includes extragenital tests, particularly at HIV diagnosis, may help curb HIV/STI transmission.

Entities:  

Keywords:  Chlamydia trachomatis; HIV diagnosis; Neisseria gonorrhoeae; Sexually transmitted infection prevalence; syphilis

Mesh:

Year:  2021        PMID: 33530892      PMCID: PMC8154699          DOI: 10.1177/0956462420987757

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.456


  24 in total

1.  WHO guidelines for HIV/STI prevention and care among MSM and transgender people: implications for policy and practice.

Authors:  Jenny Cohen; Ying-Ru Lo; Carlos F Caceres; Jeffrey D Klausner
Journal:  Sex Transm Infect       Date:  2013-11       Impact factor: 3.519

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Body Parts Matter: Social, Behavioral, and Biological Considerations for Urethral, Pharyngeal, and Rectal Gonorrhea and Chlamydia Screening Among MSM in Lima, Peru.

Authors:  Ryan Colby Passaro; Eddy R Segura; Amaya Perez-Brumer; Jeanne Cabeza; Silvia M Montano; Jordan E Lake; Jorge Sanchez; Javier R Lama; Jesse L Clark
Journal:  Sex Transm Dis       Date:  2018-09       Impact factor: 2.830

4.  An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study.

Authors:  Lindley A Barbee; Christine M Khosropour; Julia C Dombrowski; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Infect       Date:  2015-08-21       Impact factor: 3.519

5.  Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date?

Authors:  Nigel J Garrett; Nuala McGrath; Adrian Mindel
Journal:  Sex Transm Infect       Date:  2016-04-15       Impact factor: 3.519

6.  HIV Prevalence and Risk Behaviors in Male to Female (MTF) Transgender Persons in Tijuana, Mexico.

Authors:  Kristian Jesús Salas-Espinoza; Rufino Menchaca-Diaz; Thomas L Patterson; Lianne A Urada; Davey Smith; Steffanie A Strathdee; Eileen V Pitpitan
Journal:  AIDS Behav       Date:  2017-12

7.  Impact of frequent testing on the transmission of HIV and N. gonorrhoeae among men who have sex with men: a mathematical modelling study.

Authors:  Maarten Reitsema; Janneke Heijne; Maartje Visser; Ard van Sighem; Maarten Schim van der Loeff; Eline L M Op de Coul; Daniela Bezemer; Jacco Wallinga; Birgit H B van Benthem; Maria Xiridou
Journal:  Sex Transm Infect       Date:  2019-12-04       Impact factor: 3.519

Review 8.  Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?

Authors:  D A Lewis
Journal:  Sex Transm Infect       Date:  2015-04-24       Impact factor: 3.519

9.  Uptake of a Partner Notification Model for HIV Among Men Who Have Sex With Men and Transgender Women in Tijuana, Mexico.

Authors:  Shirley J Semple; Heather A Pines; Steffanie A Strathdee; Alicia Harvey Vera; Gudelia Rangel; Carlos Magis-Rodriguez; Thomas L Patterson
Journal:  AIDS Behav       Date:  2018-07

10.  Stigma and Web-Based Sex Seeking Among Men Who Have Sex With Men and Transgender Women in Tijuana, Mexico: Cross-Sectional Study.

Authors:  Cristina Espinosa da Silva; Laramie R Smith; Thomas L Patterson; Shirley J Semple; Alicia Harvey-Vera; Stephanie Nunes; Gudelia Rangel; Heather A Pines
Journal:  JMIR Public Health Surveill       Date:  2020-01-30
View more
  1 in total

1.  Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand.

Authors:  Trevor A Crowell; Sorachai Nitayaphan; Narongrid Sirisopana; Tanyaporn Wansom; Suchai Kitsiripornchai; Leilani Francisco; Qun Li; Nicole Dear; Robert J O'Connell; Punnee Pitisuttithum; Sandhya Vasan
Journal:  AIDS Res Ther       Date:  2022-06-21       Impact factor: 2.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.